This article was originally published by Pharmacy Times.

Deeper knowledge of the integral relationship between the gut and cancer therapy is critical for maintaining the integrity and efficacy of agents that have revolutionized cancer treatment over the past few decades. At the 2025 ASCO Annual Meeting this weekend, experts discussed the complexity of the gut microbiota and emerging research highlighting its role in modulating treatment response and resistance mechanisms. These insights highlight the importance of incorporating gut microbiome-focused strategies into cancer care to enhance therapeutic efficacy and support long-term disease control.

The role of the gut across disease states is a growing area of research, and emerging data show that gut bacteria are active participants in

See Full Page